drugset / Trial / NCT06980428

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428

Phase 1 Recruiting 136 enrolled AstraZeneca
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\[a\]) levels and participants with dyslipidemia.

Timeline

Start
2025-05-27
Primary completion
2026-12-04
Completion
2026-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4954 Unknown Oral

Indications